Aventus Group (ASX: AVN) is a Real Estate Investment Trust (REIT) that specialises in Large Format Retail (LFR). Traditionally these have been referred to as bulky goods retail which requires large spaces for demonstrating, viewing and purchasing.
When Aventus listed on the ASX in 2015 it had 14 sites. This has grown to an impressive portfolio of 20 locations across the Australian eastern seaboard.
So why did I buy Aventus shares?
By the nature of the business, REITs are not expected to produce double-digit growth patterns, Aventus’ occupancy rates are already high and you can only lift rents so much before tenants start looking for the nearest exit.
However, their current customer base is high-quality producing a dependable income stream. Many tenants operate under a long-term lease with either fixed-rate or CPI rent increases.
Also, Aventus operates in a very fragmented industry so any further consolidation will only benefit the larger players.
Skin In The Game
A key component of my investment thesis is a rock-solid management team that is aligned to its shareholders – Aventus has this in spades.
Most of the directors have meaningful shareholdings, but the most prominent is company founder Brett Blundy who at time of writing holds around 29% of the trust. Brett also brings significant retail experience as he was the founder of Sanity Entertainment and Bras N things and is a part-owner of BridgeClimb Sydney.
Aventus operate in an incredibly difficult retail environment, bulky goods are not essential and can be pushed aside when household budgets are tight. Any difficulties faced by key customers can potentially hinder their ability to handle rental increases.
Also, a large portion of their customers (both tenants and end users) are exposed to the Australian residential property market, so any downturn will have a flow-on impact on consumer spending.
Aventus offers a high yielding income stream that complements my growth shares. Between the world-class clients and excellent management team, I am bullish on the growth plans of this company.
After searching through a market with over 2,000 shares, our lead expert investment analyst has narrowed it down to just 2 of his favourite rapid-growth shares in a FREE report to Rask Media readers.
Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 200.
Idea #1 is taking on the world, starting with the huge USA market. In a just a few short years the company has snatched market share away from rivals and is on its way to being the market leader.
Idea #2 uses a 'printer and cartridge' type model to get large and established customers: a) using their healthcare industry-leading product, b) paying for it again and again and again... so it's little wonder this company is tipped to grow at a rapid pace in 2019.
Access the free report by clicking here now. Absolutely no credit card or payment details required.
Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).
Disclosure: At the time of writing, Anthony owns shares of Aventus.